Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous intravenous nalbuphine for postoperative analgesia after abdominal surgery
ChiCTR2600116687Phase 4Not yet recruiting
- Sponsor
- Guangdong Second Provincial General Hospital
- Start
- Jan 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nalbuphine in postoperative pain, sponsored by Guangdong Second Provincial General Hospital. Primary endpoint: Pain control achieved within 24 hours. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
nalbuphine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR2600116687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116687.